Company profilePharmaceutical#281 of 1,318 in Pakistan✓ No DRAP alerts

Citi Pharma Pvt Ltd

Pharmaceutical company · 64 brands · 48 molecules

64 registered products 39 pharmaceutical brands 48 distinct molecules 0 DRAP alerts

Company overview

64
registered products
39
pharmaceutical brands
48
distinct molecules
0
therapeutic classes
0
DRAP alerts

Citi Pharma Pvt Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 64 product registrations across 48 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Citi

51 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

51
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202651

Top molecules by brand count

Sterile Of Ceftriaxone Sodium E.Q. To Ceftriaxone7 brands
Simvastatin4 brands
Fluconazole4 brands
Cefixime4 brands
Ibuprofen4 brands
Paracetamol3 brands
Azithromycin2 brands
Ranitidine2 brands
Amlodipine2 brands

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official77 products · Rs 33.5 – Rs 762.93
Median across source: Rs 277.25

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NABIQASIM INDUSTRIES (PVT) LTD. holds 177 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
BIO LABS (PVT) LTD. holds 124 molecules not in this portfolio
000 I.UAprepitantAremetherArtemetherArtesunateAtorvastatin
STANDPHARM PAKISTAN (PVT) LTD. holds 61 molecules not in this portfolio
AlprazolamAmikacinAmoxicillinAmpicillinArtemetherAtorvastatin

Get the full profile for Citi

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.